<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85774">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02040350</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1151-9883</org_study_id>
    <nct_id>NCT02040350</nct_id>
  </id_info>
  <brief_title>Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?</brief_title>
  <official_title>Study Effect of WHO Recommended Dose of Pralidoxime in the Treatment of Organophosphorus Poisoning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheri Kashmir Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheri Kashmir Institute of Medical Sciences</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Pralidoxime, a drug used for treatment of pesticide
      poisoning (Organophosphorous poisonings)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study was designed to critically analyze the role of pralidoxime in patients
      with moderate to severe poisoning by dividing them into two comparable groups in all aspects
      and using WHO recommended dose of pralidoxime (30mg/kg bolus I.V over 20 min followed by
      8mg/kg/hr continuous infusion). This dose and continuous infusion protocol is more likely to
      maintain adequate blood concentrations of pralidoxime throughout 24 hours and thus would
      avoid any failures in effectiveness of pralidoxime because of inconsistent blood levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mortality rate</measure>
    <time_frame>upto one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of ventilation</measure>
    <time_frame>upto one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>duration of ICU stay</measure>
    <time_frame>upto one year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Deaths</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given to compare the effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pralidoxime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pralidoxime for treating organophosphorous poisoning patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralidoxime</intervention_name>
    <description>Pralidoxime was compared to placebo to study the effects of the drug on mortatlity</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pralidoxime</arm_group_label>
    <other_name>Oximes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        history of alleged organophosphorus intake age &gt; 14 years &lt; 60 years clinical signs and
        symptoms of organophosphorus poisoning.

        Exclusion Criteria:

        &lt; 14 years or &gt; 60 years of age known pregnancy pralidoxime administration at the
        transferring hospital carbamate poisoning any chronic illnesses

        â‰¥ 12 hour interval from time of poisoning to initiation of treatment pre-hospital cardiac
        or respiratory arrest.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Showkat Gurcoo, MD</last_name>
    <role>Study Director</role>
    <affiliation>SKIMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheri kashmir insititute of medical sciences</name>
      <address>
        <city>Srinagar</city>
        <state>Srinagar Kashmir</state>
        <zip>190006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. Review.</citation>
    <PMID>17706760</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheri Kashmir Institute of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Tariq Wani</investigator_full_name>
    <investigator_title>Registar</investigator_title>
  </responsible_party>
  <keyword>Pralidoxime, atropine, organophosphorous poisoning.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pralidoxime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
